Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Tirzepatide (Mounjaro, Zepbound) has been linked to rare cases of acute pancreatitis, and because similar GLP-1 based medicines caused thyroid C-cell tumors in rodents, it carries a boxed warning about medullary thyroid cancer, though a causal link in humans has not been established. Symptoms that warrant urgent attention include severe upper abdominal pain that spreads to the back, persistent vomiting, a lump or swelling in the neck, hoarseness, or difficulty swallowing. Your actual risk depends on factors such as gallstones, heavy alcohol use, high triglycerides, prior pancreatitis, and any family history of medullary thyroid carcinoma or MEN2 syndrome, and there are several important details to consider before drawing conclusions, all explained below.
Because these symptoms overlap with far more common and less serious causes, guessing on your own can lead to unnecessary worry or a dangerous delay. Take a free, instant, online symptom check to see which explanations best fit your situation and what steps make sense next.
Last reviewed for medical accuracy: 09/12/2026
Tirzepatide is a newer medication approved to help manage type 2 diabetes and support weight loss. Like all medicines, it comes with potential tirzepatide side effects. Two concerns often asked about are pancreatitis (inflammation of the pancreas) and thyroid cancer. This guide reviews what we currently know from trustworthy sources, explains warning signs, and suggests next steps if you’re taking or considering tirzepatide.
Tirzepatide (brand name Zepbound® or Mounjaro®) is a once-weekly injectable that activates two hormones:
By targeting both, tirzepatide helps:
Because of its benefits, tirzepatide use has grown quickly. But with increased use, monitoring for side effects is important.
Pancreatitis is inflammation of the pancreas, an organ that makes enzymes for digestion and hormones for blood sugar control. Symptoms can range from mild discomfort to severe, life-threatening illness.
Major drug regulators and clinical trials have reviewed tirzepatide’s safety:
The U.S. Food and Drug Administration (FDA) label for tirzepatide notes:
Watch for these signs, especially if they start or worsen after a tirzepatide dose:
If you notice these, stop tirzepatide and seek medical help promptly.
In rodent studies of tirzepatide and similar GLP-1 drugs, some rats developed thyroid C-cell tumors. This led to a precaution for humans, though there is no clear evidence of increased thyroid cancer risk in people.
The FDA label carries a boxed warning about thyroid C-cell tumors, based on animal data:
If you have a personal or family history of certain thyroid cancers, tirzepatide may not be the best choice. Talk to your doctor about alternative treatments.
Tirzepatide offers significant benefits for blood sugar control and weight loss. Serious side effects like pancreatitis or thyroid tumors are rare, but vigilance is key.
Benefits:
Potential Risks:
Monitor for Symptoms
Use a Symptom Checker
Talk to Your Doctor
Know When It’s an Emergency
Tirzepatide is a powerful tool for managing diabetes and aiding weight loss. While rare, the potential for pancreatitis or thyroid-related issues means you should stay informed and look out for warning signs. Regular check-ins with your healthcare provider and mindful self-monitoring will help you get the most benefit with the least risk.
Always speak to a doctor about anything that could be life-threatening or serious. Your healthcare team can guide you based on your history and risk factors. If you have questions about new symptoms or are worried about tirzepatide side effects, reach out right away.
Remember: your health matters most. Stay proactive, stay informed, and seek professional advice whenever you need it.
(References)
* Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, Edem D, Correa R. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023 Feb 9;7(4):bvad016. doi: 10.1210/jendso/bvad016. Epub 2023 Jan 26. PMID: 36789109; PMCID: PMC9915969.
* Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. doi: 10.3389/fendo.2023.1214334. Epub 2023 Oct 16. PMID: 37908750; PMCID: PMC10613702.
* Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024 Dec;12:100127. doi: 10.1016/j.obpill.2024.100127. Epub 2024 Aug 31. PMID: 39286601; PMCID: PMC11404059.
* Kamrul-Hasan ABM, Alam MS, Dutta D, Sasikanth T, Aalpona FTZ, Nagendra L. Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis. Endocrinol Metab (Seoul). 2025 Feb;40(1):112-124. doi: 10.3803/EnM.2024.2164. Epub 2025 Jan 15. PMID: 39814031; PMCID: PMC11898313.
* Mando N, Thomson E, Fowler M, Short L, Gillen N. Acute Pancreatitis Caused by Tirzepatide. Cureus. 2024 Dec;16(12):e76007. doi: 10.7759/cureus.76007. Epub 2024 Dec 19. PMID: 39834977; PMCID: PMC11743417.
* Khan FI, Vazquez SG, Mehdi Z, Somawardana I, Dongre R, Razmi S, Rashidi K, Shenoi J, Khan N, Dhanda A, Takashima M, Ahmed OG. Otolaryngologic Side Effects of GLP-1 Receptor Agonists. Laryngoscope. 2025 Jul;135(7):2291-2298. doi: 10.1002/lary.32061. Epub 2025 Feb 12. PMID: 39936458.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
* Tang H, Lu Y, Zhang B, Zhou T, Zhang D, Chen J, Chen Y, Asch DA, Chen Y. Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes Obes Metab. 2025 Nov;27(11):6527-6536. doi: 10.1111/dom.70054. Epub 2025 Aug 28. PMID: 40874398; PMCID: PMC12515787.
* Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025 Nov 18;86(20):1805-1819. doi: 10.1016/j.jacc.2025.08.027. Epub 2025 Aug 27. PMID: 40892610.
* Ko A, Chang YC, Bahar F, Wang TH, Xanthavanij N, Yu CC, Hsieh RJ, See XY, Lo SW, Song J, Hsia YP, Chiang CH, Xu X, Lin S, Chiang CH. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. Ann Intern Med. 2026 Feb;179(2):216-229. doi: 10.7326/ANNALS-25-02237. Epub 2025 Dec 9. PMID: 41359966.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.